Relmada Therapeutics, Inc. (OTC: RLMD) is a clinical-stage specialty pharmaceutical company developing novel versions of proven drug products as well as new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The company’s portfolio includes: d-Methadone (REL-1017), its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. For more information, please visit the company’s website at: www.relmada.com.